Paule I[au] - Search Results

Year	Number of Results
1997	1
1998	1
2011	3
2012	2
2015	1
2016	1
2017	1
2018	1
2023	0

1

Pharmacodynamic models for discrete data.

Paule I, Girard P, Freyer G, Tod M. Paule I, et al. Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Clin Pharmacokinet. 2012. PMID: 23179578 Review.

2

Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.

Nedelman J, Fisch R, Hu K, Paule I, Zhou J. Nedelman J, et al. Among authors: paule i. Clin Pharmacokinet. 2018 Jul;57(7):855-866. doi: 10.1007/s40262-017-0600-y. Clin Pharmacokinet. 2018. PMID: 29032486 Clinical Trial.

3

Impact of siponimod on vaccination response in a randomized, placebo-controlled study.

Ufer M, Shakeri-Nejad K, Gardin A, Su Z, Paule I, Marbury TC, Legangneux E. Ufer M, et al. Among authors: paule i. Neurol Neuroimmunol Neuroinflamm. 2017 Sep 13;4(6):e398. doi: 10.1212/NXI.0000000000000398. eCollection 2017 Nov. Neurol Neuroimmunol Neuroinflamm. 2017. PMID: 28955715 Free PMC article.

4

Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion.

Honma W, Gautier A, Paule I, Yamaguchi M, Lowe PJ. Honma W, et al. Among authors: paule i. Drug Metab Pharmacokinet. 2016 Jun;31(3):173-84. doi: 10.1016/j.dmpk.2015.12.003. Epub 2015 Dec 30. Drug Metab Pharmacokinet. 2016. PMID: 27238573

5

Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.

Paule I, Girard P, Tod M. Paule I, et al. Comput Methods Programs Biomed. 2011 Dec;104(3):505-13. doi: 10.1016/j.cmpb.2011.04.006. Epub 2011 May 26. Comput Methods Programs Biomed. 2011. PMID: 21616549

6

Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.

Paule I, Tod M, Hénin E, You B, Freyer G, Girard P. Paule I, et al. Cancer Chemother Pharmacol. 2012 Feb;69(2):447-55. doi: 10.1007/s00280-011-1714-9. Epub 2011 Aug 2. Cancer Chemother Pharmacol. 2012. PMID: 21809035

7

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.

Paule I, Sassi H, Habibi A, Pham KP, Bachir D, Galactéros F, Girard P, Hulin A, Tod M. Paule I, et al. Orphanet J Rare Dis. 2011 May 28;6:30. doi: 10.1186/1750-1172-6-30. Orphanet J Rare Dis. 2011. PMID: 21619673 Free PMC article. Clinical Trial.

8

In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.

Wildfeuer A, Seidl HP, Paule I, Haberreiter A. Wildfeuer A, et al. Among authors: paule i. Mycoses. 1998 Sep-Oct;41(7-8):309-19. doi: 10.1111/j.1439-0507.1998.tb00344.x. Mycoses. 1998. PMID: 9861837

9

In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.

Wildfeuer A, Seidl HP, Paule I, Haberreiter A. Wildfeuer A, et al. Among authors: paule i. Arzneimittelforschung. 1997 Nov;47(11):1257-63. Arzneimittelforschung. 1997. PMID: 9428984

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results